Invivyd Announces Preliminary Q4 2025 Revenue Growth of 25%, Ending Cash Balance of $226.7 Million and Initiates Phase 3 Pivotal Trial for COVID Antibody VYD2311

Invivyd reports Q4 2025 PEMGARDA net product revenue of $17.2 million, a 25% YoY and 31% QoQ increase. The company has a cash balance of $226.7 million after raising over $200 million in 2H 2025. Invivyd has initiated the DECLARATION Phase 3 clinical trial for its COVID vaccine-alternative antibody VYD2311 and received FDA Fast Track designation. The company has also nominated a potential best-in-class RSV antibody and is targeting preclinical measles mAb candidate selection for 1H 2026.